Reported 3 days ago
Neumora Therapeutics experienced an 80% drop in its stock value after announcing that its experimental depression drug, navacaprant, did not achieve its primary and secondary study goals in a late-stage trial. The company expressed disappointment in these findings, which contradicted earlier data, and plans to provide further updates on the study and its development pipeline at an upcoming conference.
Source: YAHOO